1884. Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials.
作者: Jonathan I Silverberg.;Andreas Wollenberg.;Adam Reich.;Diamant Thaçi.;Franz J Legat.;Kim A Papp.;Linda Stein Gold.;Jean-David Bouaziz.;Andrew E Pink.;José Manuel Carrascosa.;Barbara Rewerska.;Jacek C Szepietowski.;Dorota Krasowska.;Blanka Havlíčková.;Monika Kalowska.;Nina Magnolo.;Sylvia Pauser.;Navid Nami.;Maxwell B Sauder.;Vipul Jain.;Kamila Padlewska.;Soo Yeon Cheong.;Patricia Fleuranceau Morel.;Liliana Ulianov.;Christophe Piketty.; .
来源: Lancet. 2024年404卷10451期445-460页
Nemolizumab, an interleukin (IL)-31 receptor subunit α antagonist, inhibits the IL-31 pathway of itch and skin inflammation in atopic dermatitis. Two international phase 3 studies were done to assess the efficacy and safety of nemolizumab in atopic dermatitis. In this Article we report results for the 16-week initial treatment period of both trials.
1885. Realigning the physical activity research agenda for population health, equity, and wellbeing.
作者: Ding Ding.;Sebastien Chastin.;Deborah Salvo.;Tracy Nau.;Klaus Gebel.;Miguel Adriano Sanchez-Lastra.;Mengyun Luo.;Inacio Crochemore-Silva.;Ulf Ekelund.;Adrian Bauman.
来源: Lancet. 2024年404卷10451期411-414页 1886. Many crises, one call to action: advancing gender equality in health in response to polycrises.
作者: Rajat Khosla.;Gita Sen.;Tedros Adhanom Ghebreyesus.;Winnie Byanyima.;Sima Bahous.;Debora Diniz.;Sara Hossain.;Natalia Kanem.;Ulrika Karlsson.;Laura Laski.;Dina Mired.;Catherine Russell.;Tlaleng Mofokeng.;Achim Steiner.;Volker Türk.;Johanna Riha.
来源: Lancet. 2024年404卷10454期731-733页 1889. Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials.
作者: Robert Bissonnette.;Richard B Warren.;Andreas Pinter.;Tove Agner.;Melinda Gooderham.;Marie L A Schuttelaar.;Marie-Noëlle Crépy.;Luca Stingeni.;Esther Serra-Baldrich.;Keith Baranowski.;Sofie Korn.;Merle Kurvits.;Ursula Plohberger.;Natacha Strange Vest.;Sibylle Schliemann.; .
来源: Lancet. 2024年404卷10451期461-473页
Chronic hand eczema is a fluctuating, inflammatory, pruritic, often painful disease of hands and wrists that strongly impacts quality of life and occupational capabilities of patients. The aim of phase 3 DELTA 1 and DELTA 2 was to assess the efficacy and safety of twice-daily applications of the topical pan-Janus kinase inhibitor delgocitinib cream 20 mg/g versus cream vehicle in adults with moderate to severe chronic hand eczema.
1891. Renal cell carcinoma.
作者: Matthew Young.;Francesca Jackson-Spence.;Luis Beltran.;Elizabeth Day.;Christina Suarez.;Axel Bex.;Thomas Powles.;Bernadett Szabados.
来源: Lancet. 2024年404卷10451期476-491页
The landscape of the management of renal cell carcinoma has evolved substantially in the last decade, leading to improved survival in localised and advanced disease. We review the epidemiology, pathology, and diagnosis of renal cell carcinoma and discuss the evidence for current management strategies from localised to metastatic disease. Developments in adjuvant therapies are discussed, including use of pembrolizumab-the first therapy to achieve overall survival benefit in the adjuvant setting. The treatment of advanced disease, including landmark trials that have established immune checkpoint inhibition as a standard of care, are also reviewed. We also discuss the current controversies that exist surrounding the management of metastatic renal cell carcinoma, including the use of risk assessment models for disease stratification and treatment selection for frontline therapy. Management of non-clear cell renal cell carcinoma subtypes is also reviewed. Future directions of research, including a discussion of ongoing clinical trials and the need for reliable biomarkers to guide treatment in kidney cancer, are also highlighted.
1897. Clinical effectiveness and safety of time-lapse imaging systems for embryo incubation and selection in in-vitro fertilisation treatment (TILT): a multicentre, three-parallel-group, double-blind, randomised controlled trial.
作者: Priya Bhide.;David Y L Chan.;Doris Lanz.;Odai Alqawasmeh.;Eleanor Barry.;Dominic Baxter.;Francisco Gonzalez Carreras.;Yasmin Choudhury.;Ying Cheong.;Jacqueline Pui Wah Chung.;Bonnie Collins.;Luping Cong.;Sally Doidge.;James Heighway.;Deepali Patel.;M Carmen Pardo.;Annabel Rattos.;Annie Wright.;Julie Dodds.;Teresa Perez.;Khalid S Khan.;Shakila Thangaratinam.
来源: Lancet. 2024年404卷10449期256-265页
Time-lapse imaging systems for embryo incubation and selection might improve outcomes of in-vitro fertilisation (IVF) and intracytoplasmic sperm injection (ICSI) treatment due to undisturbed embryo culture conditions, improved embryo selection, or both. However, the benefit remains uncertain. We aimed to evaluate the effectiveness of time-lapse imaging systems providing undisturbed culture and embryo selection, and time-lapse imaging systems providing only undisturbed culture, and compared each with standard care without time-lapse imaging.
|